Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Imidacloprid + flumethrin** is a combination topical antiparasitic drug formulated in a slow-release polymer collar for dogs and cats. It contains imidacloprid (a neonicotinoid) and flumethrin (a pyrethroid). Imidacloprid acts as an agonist of insect nicotinic acetylcholine receptors, causing disruption of nervous system function. Flumethrin prolongs activation of sodium channels in insect neuron membranes, leading to persistent depolarization and neurotoxicity. The combination provides synergistic efficacy against fleas (*Ctenocephalides felis*), ticks (*Ixodes ricinus*, *Rhipicephalus sanguineus*, *Dermacentor reticulatus*), chewing lice, and some mites, offering up to 8 months of continuous protection when administered via a collar. The product is approved for use in dogs, puppies (≥7 weeks old), cats, and kittens (≥10 weeks old) and is well-tolerated with minimal systemic side effects or drug interaction risk[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on imidacloprid + flumethrin.